Product Images Clopidogrel

Clopidogrel is a medication that comes in tablet form with each tablet containing 75mg of the active ingredient. The package comes with 30 tablets and is RX only. The medication is manufactured by Accord Healthcare, Inc., Durham, NC, and repackaged by RemedyRepack Inc., Indiana, PA. The National Drug Code (NDC) is 70518-1510-00, and the Lot number and expiry are not available. Store the medication at the recommended temperature range of 20-25°C (88-77°F), and keep it away from children. The package insert should be followed for directions for use.*

This is a chart showing the cumulative event rate of fatal and non-fatal vascular events for patients taking Aspirin versus Clopidogrel Bisulfate over a follow-up period of 36 months. The chart indicates that the event rate for Aspirin is slightly higher than for Clopidogrel Bisulfate, with a statistically significant difference noted at 0.045% (p-value).*

The text shows a chart titled "Cumulative Event Rate (%) Cardiovascular death, myocardial infarction, stroke" comparing results between a placebo (with aspirin) and clopidogrel bisulfate (with aspirin) over a follow-up period of 12 months. The chart shows the placebo group has a median event rate of 16% while clopidogrel bisulfate group has a lower median event rate of less than 1.2%. It also mentions that other standard therapies were used as appropriate. Lastly, there is a significance value of P=0.00009.*

This text provides statistical data for a clinical trial of a medication called Clopidogrel. The statistic shows that the medication caused a 7% reduction in death rates compared to a placebo, with 1845 deaths occurring in the placebo group and 1726 deaths occurring in the Clopidogrel group. The reduction has a p-value of 0.03. The data is tracked up to 28 days since randomization.*

This text appears to be a portion of a clinical trial result that discusses the incidence of death, re-infarction or stroke before first discharge among two groups: one treated with placebo and the other treated with Clopidogrel. The study shows that Clopidogrel has a 9% proportional risk reduction for these incidents (with a p value of 0.002), compared to the placebo. The text also mentions randomization, up to 28 days.*

This appears to be a table showing the results of a study comparing the effectiveness of Clopidogrel and Aspirin in patients with stroke or PAD (peripheral arterial disease). The table includes the number of patients in each group, as well as the percentage of patients receiving each medication. The table also includes results from different years of the study, and a hazard ratio with a confidence interval.*